Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 12;71(6):1413-1418.
doi: 10.1093/cid/ciz995.

Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia

Erlinda R Ulloa  1   2 , Kavindra V Singh  3   4 , Matthew Geriak  5 , Fadi Haddad  6 , Barbara E Murray  3   4 , Victor Nizet  1   7 , George Sakoulas  1   5
Affiliations

Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia

Erlinda R Ulloa et al. Clin Infect Dis. .

Abstract

Cefazolin and ertapenem combination therapy was used successfully to salvage 11 cases (6 endocarditis) of persistent methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, including immediate clearance (≤24 hours) in 8 cases. While in vitro synergy was modest, cefazolin plus ertapenem exhibited synergistic action in a rat model of MSSA endocarditis. The combination of cefazolin and ertapenem provides potent in vivo activity against MSSA beyond what is predicted in vitro and warrants further clinical study in the treatment of refractory MSSA bacteremia and endocarditis.

Keywords: Staphylococcus aureus; bacteremia; cefazolin; endocarditis; ertapenem.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Efficacy of antibiotic therapy in a rat endocarditis model of infection with methicillin-susceptible Staphylococcus aureus TX0117. The results of therapy with cefazolin, ertapenem, and cefazolin-ertapenem for TX0117-infected rats are shown. Horizontal bars represent the geometric mean colony-forming unit titers. No antibiotics, filled circles; cefazolin, filled asterisks; ertapenem, open diamonds; cefazolin + ertapenem, closed diamonds. *P < .05, by 2-tailed Mann-Whitney test. **P = .005, ****P < .0001, by Kruskal-Wallis 1-way analysis of variance. Abbreviations: abx, antibiotics; CFU, colony-forming units; CZ, cefazolin; ETP, ertapenem; ns, not significant.
See this image and copyright information in PMC

References

    1. Fowler VG Jr, Olsen MK, Corey GR, et al. . Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163:2066–72. - PubMed
    1. Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis 2009; 48(Suppl 4):S231–7. - PubMed
    1. Holland TL, Arnold C, Fowler VG Jr. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA 2014; 312:1330–41. - PMC - PubMed
    1. Nannini EC, Singh KV, Murray BE. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin Infect Dis 2003; 37:1194–8. - PubMed
    1. Bryant RE, Alford RH. Unsuccessful treatment of staphylococcal endocarditis with cefazolin. JAMA 1977; 237:569–70. - PubMed

Publication types